Gilead part­ner touts an ear­ly snap­shot of its HIV vac­cine ap­proach to a cure — but there's a long path ahead

More than 2 years af­ter al­ly­ing it­self with HIV gi­ant Gilead on a com­bo ap­proach to a pos­si­ble cure, the small Span­ish biotech Aelix Ther­a­peu­tics is out with some ear­ly pos­i­tive da­ta on its vac­cine pro­gram. And they’re us­ing the up­beat as­sess­ment tout­ing the da­ta to spear­head a new fundrais­ing cam­paign for the com­pa­ny.

The biotech spot­light­ed the da­ta from their AELIX-002 tri­al, which ex­am­ined how their HTI T-cell ther­a­peu­tic HIV vac­cine could help pa­tients stay off an­ti­retro­vi­ral ther­a­py, or ART.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER